Regression of metastatic carcinoid tumors with octreotide therapy: Two case reports and a review of the literature

Leong, Wey L.; Pasieka, Janice L.

doi:10.1002/jso.10062

Cited by 59 publications

(17 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17] Somatostatin analogues may have antitumour effects 18 and there are occasional reports of dramatic clinical responses. 19 However, tumour regression is modest and a survival benefit has not been definitively proven.…”

mentioning

confidence: 99%

Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours

Turner

Johnston

McCance

et al. 2006

Gut

108

View full text Add to dashboard Cite

Background and aims: Midgut carcinoid tumours are uncommon tumours with an unpredictable clinical behaviour and few useful prognostic markers. Somatostatin analogues are widely used in treatment but a survival advantage has not been proven. We analysed features associated with poor prognosis and assessed the clinical implications of the biochemical response to therapy. Methods: Clinical and biochemical data were collected for patients with midgut carcinoid tumours attending a tertiary referral neuroendocrine clinic from 1978 to 2000. Using death as the end point, univariate and multivariate survival analyses were performed to identify prognostic indicators. The significance of altering biomarkers with therapy was also studied by including repeated measurements of the most prognostic biochemical parameter in a time dependent covariate survival analysis. Results: We identified 139 patients with sufficient data for our analyses. Factors associated with a poor outcome on univariate analysis included: plasma neurokinin A (NKA), urinary 5-hydroxyindolacetic acid output, age, and >5 liver metastases. Plasma NKA was the strongest and only independent predictor of outcome on multivariate analysis. Patients in whom NKA continued to rise despite somatostatin analogues had a significantly worse survival than those in whom NKA stabilised or fell (one year survival rate 40% v 87%). Time dependent covariate analysis concluded that survival was better predicted by the most recent plasma NKA value rather than by the initial value. Conclusions: Plasma NKA is an accurate marker of prognosis for midgut carcinoid tumours. This is the first paper to support a survival advantage in patients in whom plasma NKA is altered by somatostatin analogues.

show abstract

mentioning

confidence: 99%

Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours

Turner

Johnston

McCance

et al. 2006

Gut

108

View full text Add to dashboard Cite

show abstract

“…Previous studies reported that OCT is an antioxidant that shows protective effects against digestive system tumors and oxidative damage (Leong and Pasieka, 2002). Previously, we also reported that BLM induces severe stress and increases free radical levels, whereas OCT administration significantly reduces this damage.…”

Section: Discussionmentioning

confidence: 92%

The effect of octreotide, an analog of somatostatin, on bleomycin-induced interstitial pulmonary fibrosis in rats

Tuğ

Kara

Karaoğlu

et al. 2012

Drug and Chemical Toxicology

View full text Add to dashboard Cite

In this study, octreotide (OCT), a synthetic somatostatin analog, was tested for its beneficial effects in the prevention of interstitial pulmonary fibrosis (IPF) induced by bleomycin (BLM) in rats by histological examination and by evaluating tissue OH-proline levels. Thirty male Wistar rats were divided randomly into three groups: group I: intratracheal (i.t.) BLM (7.5 mg/kg, single dose) + saline solution [0.9% NaCl, subcutaneously (s.c.), once-daily for 7 days]; group II: i.t. BLM (7.5 mg/kg, single dose) + OCT acetate (82.5 µg/kg, s.c., once-daily for 7 days); and the control group. At the end of the 7 days, lung tissues were excised and examined by histopathological methods. Levels of tissue hydroxyproline (OH-proline) were determined. BLM administration resulted in prominent histopathologic findings, such as diffuse alveolar damage and interstitial pulmonary fibrosis, as well as a significant increase in OH-proline level, as compared to controls. OCT application explicitly attenuated the histopathologic changes to a significant extent. OCT decreased paranchymal fibrosis and structural deformities in BLM-induced lung fibrosis. These results suggest that OCT administration to rats with BLM-induced IPF has a protective effect. Further studies are necessary to reveal the molecular mechanism(s) of OCT-induced protective effect.

show abstract

“…Leong and Pasieka reported 2 cases of metastatic carcinoid tumors where octreotide was given for symptomatic treatment before the debulking surgery. Previously seen radiographic metastatic lesions were found to be regressed completely on laparotomy [19]. …”

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Tumor (Carcinoid Tumor) of the Testis: A Case Report with Review of Literature

Heimann

2015

Am J Case Rep

View full text Add to dashboard Cite

Patient: Male, 34Final Diagnosis: Primary neuroendocrine tumor of the testisSymptoms: Pain • swellingMedication: NoneClinical Procedure: Radical orchiectomySpecialty: OncologyObjective:Rare diseaseBackground:The term carcinoid (Karzinoide) was coined by German pathologist Oberndorfer in 1907. Primary testicular carcinoid tumors (TCT) are rare, constituting 0.23% of all testicular tumors. In this report we describe a case of primary TCT of the testis and present the results of an extensive literature review to cover all the aspects of carcinoid tumor, including the definition, classification, origin, presentation, diagnostic evaluation, management, prognosis, and follow-up.Case Report:A 34-year-old male presented with chronic right scrotal swelling with recent onset of pain. Radical orchiectomy revealed a solid intratesticular tumor confined to the testis and epididymis, without lymphovascular invasion. Histology was consistent with neuroendocrine carcinoma. The tumor was staged as pT1 N0 M0 S2. Immunohistochemistry was positive for neuroendocrine markers. An extratesticular carcinoid tumor was ruled out. Urinary excretion of 5-hydroxyindoleacetic acid and Chromogranin A were within normal range.Conclusions:It is important to follow serotonin levels since the elevated levels of serotonin can cause carcinoid heart disease. If metastatic lesions are not accessible for resection, a trial of octreotide therapy can be given. This case also adds to the rare reports in the literature of primary carcinoid tumors of the testis having low malignant potential. The literature review highlights new diagnostic and therapeutic interventions and stresses the importance of long-term follow-up due to evidence of delayed metastasis or recurrences and also due to emergence of new complications as a result of improved prognosis and prolonged survival.

show abstract

Regression of metastatic carcinoid tumors with octreotide therapy: Two case reports and a review of the literature

Cited by 59 publications

References 34 publications

Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours

Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours

The effect of octreotide, an analog of somatostatin, on bleomycin-induced interstitial pulmonary fibrosis in rats

Primary Neuroendocrine Tumor (Carcinoid Tumor) of the Testis: A Case Report with Review of Literature

Contact Info

Product

Resources

About